US47010C4096
© ACCESS Newswire
29.01.2025
JAGX
LISTED
NASDAQ
Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO
News Preview
Gastrointestinal disorders are the most frequently reported adverse effects during clinical trials of GLP-1 agonists; GI adverse events usually develop in 40-70% of treated patients, and have been reported in up to 85%Crofelemer, approved by the FDA under the brand name Mytesi® for HIV-related diarrhea, has demonstrated a significant benefit i...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
22.01.2025
JAGX
LISTED
NASDAQ
Jaguar Health Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Crofelemer for the Rare Disease Indication of Microvillus Inclusion Disease (MVID), with Proof-of-Concept (POC) Data Potentially Available H1 2025
News Preview
Trial taking place at Sheikh Khalifa Medical City, a flagship tertiary hospital in the United Arab EmiratesPOC data generated from this study could potentially lead to reimbursed early patient access in certain European countries for crofelemer for MVIDCrofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan Drug Designatio...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
10.01.2025
JAGX
LISTED
NASDAQ
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN FRANCISCO, CA / ACCESSWIRE / January 10, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective January 8, 2025, the Company granted 15,000 restricted stock units (RSUs) to New Employee 1, 15,000 RSUs to New Employee 2, and 45,000 RSUs to New Employee 3.The RSUs for New Employee...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© ACCESS Newswire
08.01.2025
JAGX
LISTED
NASDAQ
Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit & January 14 at Biotech Showcase
News Preview
SAN FRANCISCO, CA / ACCESSWIRE / January 8, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will participate in a virtual fireside chat on January 13, 2025 at the Lytham Partners 2025 Investor Healthcare Summit and in person on January 14, 2025 at Biotech Showcase.Participation Ins...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© ACCESS Newswire
07.01.2025
JAGX
LISTED
NASDAQ
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum
News Preview
Magdalena aiming to submit Investigational New Drug (IND) application in early 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ADHD and schizophrenia, with 1-2 additional IND applications filed in 2025 SAN FRANCISCO, CA / ACCESSWIRE / January 7, 2025 / Jaguar Health, Inc...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
19.12.2024
JAGX
LISTED
NASDAQ
Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications
News Preview
Magdalena to explore coca leaf's possible therapeutic benefit for treatment of potentially ADHD or other neuropsychiatric indicationsThe import was conducted in collaboration with the government of PeruSteven King, Ph.D. of Jaguar to speak about the potential promise of coca-based Botanical Drugs at the February 2025 Wisdom of the Leaf Coca Summit...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
18.12.2024
JAGX
LISTED
NASDAQ
Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder
News Preview
The study is one of five clinical efforts - three proof-of-concept investigator-initiated trials (IIT) and two Phase 2 studies - of crofelemer for the rare disease indications of MVID and/or short bowel syndrome with intestinal failure (SBS-IF) in the US, EU, and/or Middle East/North Africa regions; availability of first IIT proof-of-concept result...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
17.12.2024
JAGX
LISTED
NASDAQ
FDA Approves Orphan-Drug Designation for Jaguar Health’s Crofelemer for Treatment of Diarrhea in Cholera
News Preview
World Health Organization (WHO) has classified the global resurgence of cholera at the highest internal level for emergencies; 1.3 to 4 million cholera cases and 21,000 to 143,000 cholera-related deaths occur each year worldwideCholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio choleraeCrofelemer pr...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
13.12.2024
JAGX
LISTED
NASDAQ
Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer
News Preview
Crofelemer is the subject of five clinical efforts - three proof-of-concept investigator-initiated trials (IIT) and two Phase 2 studies - for the rare disease indications of microvillus inclusion disease (MVID) and/or short bowel syndrome with intestinal failure (SBS-IF) in the US, EU, and/or Middle East/North Africa regions; availability of IIT pr...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
12.12.2024
JAGX
LISTED
NASDAQ
Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS)
News Preview
Adult patients with breast cancer are a prespecified subgroup of the recently conducted phase 3 OnTarget trial evaluating crofelemer for prophylaxis of CTDThe majority of patients in the OnTarget placebo group on abemaciclib and pertuzumab-based therapies required dose reduction or elimination SAN FRANCISCO, CA / ACCESSWIRE / December 12, 2024 / Ja...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
09.12.2024
JAGX
LISTED
NASDAQ
Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS)
News Preview
Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of CTD SAN FRANCISCO, CA / ACCESSWIRE / December 9, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that the data from the recently conducted analys...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
06.12.2024
JAGX
LISTED
NASDAQ
U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health’s Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins
News Preview
The study is one of five clinical efforts - three IIT proof-of-concept studies and two Phase 2 studies - of crofelemer for the rare disease indications of SBS-IF and/or microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder, in the US, EU, and/or Middle East/North Africa (MENA) regions; availability of IIT proof-of-concept...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© ACCESS Newswire
05.12.2024
JAGX
LISTED
NASDAQ
Article about Canalevia-CA1, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for the Treatment of Chemotherapy-Induced Diarrhea in Dogs, Published in PetVet Magazine
News Preview
Canalevia®-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based drug sustainably harvested from the Croton lechleri treeCrofelemer, the active ingredient in Canalevia CA-1, is the subject of Jaguar's recently conducted Phase 3 OnTarget trial in humans for cancer therapy-related diarrhea SAN FRANCISCO, CA / ACCES...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
02.12.2024
JAGX
LISTED
NASDAQ
Jaguar Health Participating in December 3-5 Pet Connect Conference with Goal of Identifying Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
News Preview
Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drugs to treat general diarrhea in dogsCanalevia®-CA1, Jaguar's first-generation antisecretory drug for the treatment of chemotherapy-induced diarrhea i...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
25.11.2024
JAGX
LISTED
NASDAQ
Jaguar Health Presenting December 3rd at NobleCon20 and December 5th at the Emerging Growth Conference
News Preview
SAN FRANCISCO, CA / ACCESSWIRE / November 25, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present in person on December 3, 2024 at NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference, and present virtually on December 5, 2024 at the Emerg...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
22.11.2024
JAGX
LISTED
NASDAQ
Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
News Preview
Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drugs to treat general diarrhea in dogsCanalevia®-CA1, Jaguar's first-generation antisecretory drug for the treatment of chemotherapy-induced diarrhea i...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
19.11.2024
JAGX
LISTED
NASDAQ
Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe”
News Preview
Established in Milan, Italy in 2021, Napo Therapeutics is focused on expanding access to crofelemer, Jaguar's novel oral plant-based prescription drug, in Europe for orphan and/or rare diseases SAN FRANCISCO, CA / ACCESSWIRE / November 19, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Jaguar family company Napo Therapeutics...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
13.11.2024
JAGX
LISTED
NASDAQ
Jaguar Health Reports Third Quarter 2024 Financial Results
News Preview
The combined net Q3 2024 revenue of approximately $3.1 million for prescription and non-prescription products, including license revenue, increased approximately 14% versus net Q2 2024 revenue of $2.7 million and 11% versus net Q3 2023 revenue of $2.8 millionJaguar reported significant results in breast cancer patients in its phase 3 OnTarget trial...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
11.11.2024
JAGX
LISTED
NASDAQ
Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates
News Preview
Click here to register for investor webcastCompany plans to file its Earnings Report on November 13, 2024 on Form 10-Q for the quarter ended September 30, 2024 SAN FRANCISCO, CA / ACCESSWIRE / November 11, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Wednesday, November 13, 2024 at 8:...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
06.11.2024
JAGX
LISTED
NASDAQ
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs
News Preview
Canalevia®-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDABy prescription only, Canalevia-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree SAN FRANCISCO, CA / ACCESSWIR...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
04.11.2024
JAGX
LISTED
NASDAQ
Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)
News Preview
Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD)A second late-breaking abstract related to the OnTarget trial, based on data from the placebo arm of the study, has also been accepted for a poster presentation at SABCS...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
29.10.2024
JAGX
LISTED
NASDAQ
Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting
News Preview
It is estimated that 10-15% of people in the United States have IBS SAN FRANCISCO, CA / ACCESSWIRE / October 29, 2024 / Jaguar Health, Inc.(NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo") today announced that the abstracts are now available for two independent investigator-initiated studies of crofelemer, Na...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
16.10.2024
JAGX
LISTED
NASDAQ
Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S.
News Preview
Gelclair® is the company's third commercialized prescription productOral mucositis, also called "chemo mouth," a painful inflammation of the mouth's mucous membranes, has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task forceSevere mucositis/pharyngitis occurred in 70...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
11.10.2024
JAGX
LISTED
NASDAQ
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN FRANCISCO, CA / ACCESSWIRE / October 11, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective October 7, 2024, the Company granted 80,000 restricted stock units (RSUs) to New Employee 1 and 15,000 RSUs to each of four other new employees ("New Employees 2-5").The RSUs...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
10.10.2024
JAGX
LISTED
NASDAQ
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum
News Preview
Magdalena aiming to submit Investigational New Drug (IND) application in early 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ADHD and schizophrenia, with 1-2 additional IND applications filed in 2025 SAN FRANCISCO, CA / ACCESSWIRE / October 10, 2024 / Jaguar Health, In...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
08.10.2024
JAGX
LISTED
NASDAQ
Jaguar Health Submits Abstract for First-of-Kind Study Evaluating the Impact of Diarrhea from Cancer Therapies in Breast Cancer Patients Who Received Placebo in its OnTarget Phase 3 Trial
News Preview
SAN FRANCISCO, CA / ACCESSWIRE / October 8, 2024 / Jaguar Health, Inc.(NASDAQ:JAGX) ("Jaguar") today announced that a late-breaking abstract evaluating the incidence, severity and management of diarrhea from targeted therapies with or without standard chemotherapy in the cohort of adult patients with breast cancer in the placebo group of...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
01.10.2024
JAGX
LISTED
NASDAQ
Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer
News Preview
Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of cancer therapy-related diarrheaOnTarget results in breast cancer patients have been submitted to a relevant oncology conference SAN FRANCISCO, CA / ACCESSWIRE / October 1, 2024 / Jaguar Health, Inc. (NASDAQ...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
26.09.2024
JAGX
LISTED
NASDAQ
Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patients and
News Preview
Jaguar's commercial focus on cancer supportive care aims to use the best tools and techniques that assess the quality of life of cancer patients and survivors and deliver solutions to address these unmet needs - Commonly used tools and techniques fail to measure what patients are most concerned aboutJaguar family company Napo Pharmaceuticals sponso...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
25.09.2024
JAGX
LISTED
NASDAQ
Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
News Preview
SAN FRANCISCO, CA / ACCESSWIRE / September 25, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference , taking place virtually on Tuesday, October...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
24.09.2024
JAGX
LISTED
NASDAQ
Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch
News Preview
Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task forceUp to 40% of all patients treated with chemotherapy develop oral mucositis, and this percentage rises to approximately 90% for patients with head and neck cancers treated w...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
